Synonym
Etofylline; Oxyphylline; Dilaphyllin; Frekaphyllin; Soluphylline; Theophylline; Etophylline; Hydroxyethyltheophylline; NSC-113373; NSC 113373; NSC113373;
IUPAC/Chemical Name
7-(2-hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione
InChi Key
NWPRCRWQMGIBOT-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3
SMILES Code
O=C(N1C)N(C)C2=C(N(CCO)C=N2)C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
224.22
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lücker PW, Wetzelsberger K, Erking W, Donike M. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. Arzneimittelforschung. 1980;30(11b):2045-53. German. PubMed PMID: 7194058.
2: Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Ajjala DR. A simple and rapid HPLC/UV method for the simultaneous quantification of theophylline and etofylline in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):271-6. Epub 2006 Nov 15. PubMed PMID: 17110179.
3: Erking W, Lücker PW, Niebch G, Thiemer K, Wetzelsberger K. [Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)]. Arzneimittelforschung. 1981;31(2):371-9. German. PubMed PMID: 7194656.
4: Ujházy E, Onderová E, Horáková M, Bencová E, Durisová M, Nosál R, Balonová T, Zeljenková D. Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice. Pharmacol Toxicol. 1989 Mar;64(3):286-90. PubMed PMID: 2726692.
5: Ditschuneit HH, Hutt V, Klör HU, Ditschuneit H. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)]. Arzneimittelforschung. 1980;30(11b):2063-7. German. PubMed PMID: 7194061.
6: Sim AK, Davies ME, McCraw AP, Metz G. Effect of etofylline clofibrate on experimental thrombosis and platelet function. Arzneimittelforschung. 1980;30(11b):2042-5. PubMed PMID: 7194057.
7: Zuidema J, Verhoeven J, Merkus FW. Pharmacokinetics of etofylline after intravenous and oral administration to humans. Int J Clin Pharmacol Ther Toxicol. 1981 Jul;19(7):310-3. PubMed PMID: 7263108.
8: Jain JK, Prakash MS, Mishra RK, Khandhar AP. Simultaneous determination of multi drug components Theophylline, Etofylline, Guaiphenesine and Ambroxol Hydrochloride by validated RP-HPLC method in liquid dosage form. Pak J Pharm Sci. 2008 Apr;21(2):151-8. PubMed PMID: 18390446.
9: Schneider J, Mühlfellner G, Mühlfellner O, Hausmann L, Schubotz R. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. Arzneimittelforschung. 1980;30(11b):2059-62. German. PubMed PMID: 7194060.
10: Sterner W, Chibanguza G, Metz G. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)]. Arzneimittelforschung. 1980;30(11b):2038-41. German. PubMed PMID: 7194056.
